Clinical Trials Logo

Spondylitis, Ankylosing clinical trials

View clinical trials related to Spondylitis, Ankylosing.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 3

NCT ID: NCT01358175 Active, not recruiting - Clinical trials for Ankylosing Spondylitis

16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis

MEASURE 1
Start date: October 2011
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.

NCT ID: NCT01289743 Active, not recruiting - Clinical trials for Ankylosing Spondylitis

Etanercept (Enbrel) in Ankylosing Spondylitis

Enbrel_AS-2
Start date: February 2002
Phase: Phase 2
Study type: Interventional

The study has the aim to investigate the efficacy and safety of etanercept in patients with active ankylosing spondylitis (AS) over 520 weeks.

NCT ID: NCT01072058 Active, not recruiting - Clinical trials for Arthritis, Rheumatoid

Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker

Start date: February 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine possible alterations in cardiac function in patients with Rheumatoid Arthritis and Ankylosing Spondylitis under anti-TNF therapy, without clinical heart disfunction at baseline, using highly sensitive non-invasive methods.

NCT ID: NCT00243750 Active, not recruiting - Clinical trials for Ankylosing Spondylitis

Methotrexate in Ankylosing Spondylitis (MTX in AS)

Start date: September 2003
Phase: Phase 2
Study type: Interventional

Assessing the efficacy and tolerability of methotrexate 15mg sc in the first month of treatment- if well tolerated methotrexate 20mg sc in the following 3 months in patients with active anklyosing spondylitis

NCT ID: NCT00235105 Active, not recruiting - Clinical trials for Ankylosing Spondylitis

D2E7-Early AS

Start date: March 2005
Phase: Phase 2/Phase 3
Study type: Interventional

Reduction of signs and symptoms in patients with moderate to severely early axial spondyloarthritis (without radiological sacroiliitis) who have had an inadequate response to or do not tolerate NSAID therapy. Study Objectives:Efficacy –To assess whether patients with moderate to severely active early axial spondyloarthritis (without radiological sacroiliitis) will show response when adalimumab is added to the pre-existing or in case of intolerance to NSAID therapy. Response will be measured at week 12 by change of efficacy parameters compared to baseline.Safety – To demonstrate the safety of adalimumab in study patients with moderate to severely active early axial spondyloarthritis (without radiological sacroiliitis) in patients who have had an inadequate response to or do not tolerate NSAID therapy.